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Abstract
Background: Deutetrabenazine, an inhibitor of vesicular monoamine transporter type 2 (VMAT2) depletes presynaptic dopamine and is useful in the treatment of
hyperkinetic movement disorders. This study explored the safety, tolerability, and preliminary efficacy of deutetrabenazine in adolescents with moderate-to-severe
tics associated with Tourette syndrome (TS).
Methods: In this open-label study of 12–18-year-old patients with TS-related tics, deutetrabenazine was titrated up to 36 mg/day over 6 weeks to adequately
suppress tics without bothersome adverse effects (AEs), followed by maintenance at optimal dose for 2 weeks. An independent blinded rater assessed tic severity using
the Yale Global Tic Severity Scale (YGTSS), which was the primary outcome measure. Secondary outcome measures included the TS Clinical Global Impression
(TS-CGI) and TS Patient Global Impression of Change (TS-PGIC).
Results: Twenty-three enrolled patients received deutetrabenazine and had at least 1 post-baseline YGTSS assessment. The mean (SD [standard deviation])
baseline YGTSS Total Tic Severity Score (TTS) was 31.6 (7.9) and had decreased by 11.6 (8.2) points at week 8, a 37.6% reduction in tic severity (p,0.0001). The
TS-CGI score improved by 1.2 (0.81) points (p,0.0001) and the TS-PGIC results at week 8 indicated that 76% of patients were much improved or very much
improved compared with baseline. The mean (SD) daily deutetrabenazine dose at week 8 was 32.1 (6.6) mg (range 18–36 mg). One week after withdrawal of
deutetrabenazine, the TTS scores increased by 5.6 (8.4) points, providing confirmation of the drug effect. No serious or severe adverse events were reported.
Discussion: The results of this open-label 8-week study suggest that deutetrabenazine is safe and associated with improvement in tic severity in adolescents with
TS and troublesome tics.
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Introduction
Tourette syndrome (TS) is a childhood-onset complex neurodeve-
lopmental disorder characterized by multiple motor and phonic tics
and a wide range of neurobehavioral problems, including attention
deficit with hyperactivity (ADHD) and obsessive–compulsive disorder.1
The Diagnostic and Statistical Manual of Mental Disorders Fifth
Edition (DSM-V) defines TS by the presence of multiple motor and
phonic tics that persist for at least 1 year and with age of onset prior
to 18 years.2
The pharmacological treatment of TS consists of antidopaminergic
agents and a wide array of other psychotropic medications, and toler-
ability to these treatments is often compromised by the frequent
occurrence of adverse effects (AEs).3,4 Furthermore, a sizeable number
of patients fail to obtain satisfactory relief with conventional medica-
tions, and some experience severe disabling tics requiring surgical
intervention.5,6 There is, therefore, an unmet need for safer, more
effective pharmacological treatments of tics and behavioral comorbid-
ities associated with TS.
Tetrabenazine, approved in the United States for the treatment of
chorea associated with Huntington disease, has shown promise in the
treatment of a variety of hyperkinetic movement disorders, including
tics associated with TS.7–9 As a vesicular monoamine transporter, type
2 (VMAT2) inhibitor, tetrabenazine depletes dopamine presynapti-
cally. Although generally effective in reducing abnormal involuntary
movements without causing tardive dyskinesia (TD), tetrabenazine is
associated with relatively frequent and often intolerable AEs, including
somnolence, nausea, depression, insomnia, akathisia, and parkinson-
ism8,9 as well as rare episodes of oculogyric reactions and other
dystonic responses.10–12 Tetrabenazine is an immediate-release formu-
lation, and, accordingly, some AEs such as somnolence and akathisia,
are often associated with peak concentration immediately after dosing.
Furthermore, the active metabolites of tetrabenazine, alpha-dihydro-
tetrabenazine (a-HTBZ) and beta-dihydrotetrabenazine (b-HTBZ),
have short half-lives, thus requiring repeated dosing of tetrabenazine
three times per day or more. The United States Food and Drug
Administration (FDA) recommends that patients taking more than
50 mg of tetrabenazine daily are genotyped for polymorphisms in the
CYP2D6 gene, as cytochrome P450 2D6 is involved in the metabolism
of a-HTBZ and b-HTBZ. There is, however, little evidence that
extensive metabolizers experience fewer AEs than poor metabolizers.13
To address the limitations of tetrabenazine, Auspex, a wholly owned
subsidiary of Teva Pharmaceutical Industries (Petah Tikva, Israel)
has developed deutetrabenazine, a deuterated form of tetrabenazine
(also referred to as SD-809 or TEV-50717). Deutetrabenazine is a
VMAT2 inhibitor structurally related to tetrabenazine, with two
trideuteromethoxy groups (–OCD3) installed at the 9 and 10 positions
instead of the two methoxy groups (–OCH3) at the corresponding
positions in tetrabenazine. Deuterium placement at these positions
attenuates metabolism and thus confer important pharmacokinetic
advantages compared with tetrabenazine, including longer half-lives
of circulating active metabolites (total [a+b]-HTBZ), reduced meta-
bolic variability and increased the area under the concentration–time
curve (AUC) with lower doses and lower peak concentrations with-
out changing the target pharmacology.14,15 Following oral admini-
stration in healthy adults, plasma concentrations of both deutetrabe-
nazine and tetrabenazine are low and transient, suggesting rapid
and extensive conversion of both parent drugs to their a-HTBZ and
b-HTBZ metabolites, which are then metabolized by CYP2D6 to yield
O-desmethyl HTBZ.15 This reduction in breakdown of the active
metabolites results in a substantially lower (about half) dose than
tetrabenazine to achieve a similar AUC.15 As the usual starting dose
for tetrabenazine in suppressing tics in TS is 12.5 mg/day,16 a starting
dose of 6 mg of deutetrabenazine was employed in this trial because it
was expected to deliver an AUC of total (a+b)-HTBZ that was similar
to the 12.5 mg of tetrabenazine but with a lower peak concentra-
tion. Because of these pharmacokinetic advantages, deutetrabenazine
requires less frequent dosing relative to tetrabenazine and may reduce
AEs, particularly drowsiness, often encountered with tetrabenazine,
probably related to its high Cmax within 1 hour after administra-
tion. Data in patients receiving deutetrabenazine for the treatment of
chorea associated with Huntington disease demonstrated a favorable
safety profile with low rates of neuropsychiatric AEs.17
Here, we report the results of a phase 1b open-label study of
deutetrabenazine in adolescents with troublesome motor and phonic
tics. The primary objective of the study is to generate safety and
efficacy data about deutetrabenazine in patients with TS that will




This was an open-label, prospective study to evaluate the safety and
preliminary efficacy of deutetrabenazine for the treatment of troublesome
motor and phonic tics in adolescents with TS (ClinicalTrials.gov identi-
fier: NCT02674321). The study was conducted in accordance with the
principles of Good Clinical Practice, and with the FDA guidelines on
safety monitoring by Institutional Review Boards for Human Research.
Written informed consent by the parent/guardian and assent of the
adolescent was obtained before study participation.
The study consisted of three periods: a screening period, a treatment
period comprising a 6-week titration phase and 2-week maintenance
phase, and a 1-week washout period with no treatment. Although our
primary objective was to determine safety and dosing of deutetrabe-
nazine in the childhood population, we also sought to obtain informa-
tion about its efficacy. Throughout the study, an independent rater
assessed tic severity with the Yale Global Tic Severity Scale (YGTSS),
which was our primary outcome measure. The blinded independent
rater did not have knowledge of the patient’s clinical care, including
medications or reports of AEs. Secondary outcome measures included
the TS Clinical Global Impression (TS-CGI) and TS Patient Global
Impression of Change (TS-PGIC). As the circulating drug is
metabolized by the hepatic enzyme cytochrome P450 (CYP) 2D6, a
blinded assessment of the CYP2D6 genotype was conducted before
treatment.
Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine Use in Tourette Syndrome
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services2
During the screening period, patients underwent a comprehensive
evaluation including physical and neurological examinations, assess-
ment of tic severity, medical history, laboratory examination, and
12-lead electrocardiogram (ECG). Patients meeting the selection
criteria received 8 weeks of treatment with deutetrabenazine, including
a titration period of 6 weeks followed by a maintenance period of
2 weeks. During titration, patients and their parents/guardians
interacted weekly with the clinical research staff (clinic visits at weeks
2 and 4, and telephone contacts at weeks 1, 3, 5, and 6) in order to
evaluate safety and tolerability, and to identify a dose of deutetrabe-
nazine that adequately reduced tics and was well tolerated. The dose of
deutetrabenazine started at 6 mg/day and was increased weekly until
there was adequate reduction of tics, the patient experienced a
protocol-defined ‘‘clinically significant’’ AE, or the maximal allowable
dose was reached. Safety evaluations included monitoring for AEs,
assessment of vital signs, and standardized rating scales for depression
and suicidal ideation and behavior (Beck Depression Inventory II
(BDI-II), the Children’s Yale–Brown Obsessive Compulsive Scale (CY-
BOCS) and the Columbia Suicide Severity Rating Scale (C-SSRS).
At weeks 2 and 4, the YGTSS and TS-CGI were assessed by an
independent rater.
During the maintenance period, patients continued to receive
the dose established during titration, although dose reductions for
treatment-emergent adverse effects, were allowed. Patients returned
to the clinic at week 8 for a complete evaluation, including physical
and neurological examination, clinical laboratory tests, 12-lead ECG
and performance of all rating scales, including the YGTSS and
TS-CGI, which were assessed by an independent rater. Patients
discontinued deutetrabenazine treatment at the week 8 visit and
returned at week 9 for evaluation of safety and tic severity. Patients
also had follow-up telephone contact 4 weeks after their last dose of
deutetrabenazine to assess adverse events.
Participants
Male and female patients, age 12–18 years, with a diagnosis of TS
and troublesome tics were eligible to participate in the study. Eligibility
criteria included a DSM-5 diagnosis of TS, manifest motor and/or
phonic tics within 3 months before the screening visit, and YGTSS
Total Tic Severity Score (TTS) >_ 19 and TS-CGI score >_ 4 at
screening.
Patients were excluded if they had a neurological disorder other
than TS or a serious untreated or undertreated psychiatric illness, such
as active suicidal ideation or suicide attempt, depression, schizo-
phrenia, or bipolar disorder at screening. Patients on stable anti-
depressant therapy for at least 8 weeks before screening could enroll
but were excluded if they had received the following medica-
tions within 14 days of screening: tetrabenazine, typical and atypical
antipsychotics, benzodiazepines, topiramate, metoclopramide, mono-
amine oxidase inhibitors, levodopa, or reserpine within 21 days.
Guanfacine or clonidine within 7 days, reserpine with 21 days, depot
neuroleptics, botulinum toxin within 3 months of screening, and
participation in an investigational drug or device study within 30 days
of screening were prohibited. Other exclusionary criteria were prior
treatment with deep brain stimulation for tics, alcohol or substance
abuse within 12 months of screening, and a QT interval (corrected by
Fridericia’s formula) .440 ms on a 12-lead ECG.
Treatment protocol
Deutetrabenazine dosing was individualized for each patient.
The starting dose was 6 mg/day and was increased on a weekly
basis by 6 mg during the titration period to identify a dose that
adequately reduced tics and was well tolerated. Daily doses of 12 mg
and higher were administered in two divided doses with food,
approximately 10 hours apart during the day. The maximum
daily dose of deutetrabenazine was 36 mg/day, less than the 48 mg
maximum allowed dose used in studies of deutetrabenazine in an adult
population.17
Assessments and outcome measures
Efficacy measures included a change from baseline to week 8 in the
YGTSS TTS (the primary outcome measure), the TS-CGI, and the
TS-PGIC at week 8. The YGTSS evaluates tics during the previous
week and has two components: the TTS and the Tic-Related
Impairment Score (TIS).18 The TTS has a total of five domains,
number, frequency, intensity, complexity, and interference, each rated
on a 0–5 scale for both motor and phonic (vocal) tics (total maximum
TTS is 50). The TIS ranges between 0 and 50. Thus the maximum
total YGTSS score, or the Global Severity Score (GSS, TTS plus TIS)
is 100. The TS-CGI is a 7-point Likert scale that allows clinicians to
use all available information to assess the impact of tics on the patient’s
quality of life and is rated as follows: 1 (normal), 2 (borderline), 3 (mild),
4 (moderate), 5 (marked), 6 (severe), and 7 (extreme).19 The TS-PGIC
is a single-item questionnaire that asks patients to assess their overall
condition after initiating therapy. It consists of a 7-point Likert scale,
ranging from very much worse (–3) to very much improved (+3).20
Figure 1 provides a list and timeline of the various assessments
performed during the course of the trial.
Safety and tolerability were assessed throughout the study by
monitoring AEs, physical and neurological examinations, vital signs,
12-lead ECGs, clinical chemistry and hematology tests, the BDI-II,
CY-BOCS, and C-SSRS rating of suicidal behaviors.
Statistical analyses
Since this was an exploratory trial, intended to be used in the design
of subsequent studies, no sample power analysis was done. Efficacy
analyses were conducted on patients who received at least one dose of
the study drug and had at least one post-baseline YGTSS assessment
(efficacy population) and were based on observed scores; missing data
were not imputed for these analyses. Sensitivity analyses using the last
observation carried forward method to impute missing data at week 8
were conducted for efficacy endpoints to assess the robustness of the
efficacy data. If a patient’s value at week 8 was missing, the most recent
non-missing value was carried forward.
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For YGTSS and TS-CGI analyses, the change from baseline,
percentage change from baseline, change from week 8 to week 9, and
percentage change from week 8 to week 9 were analyzed using two-
sided, one-sample t-tests. The number and percentage of patients in
each TS-CGI category were tabulated by visit, including those whose
symptoms improved or worsened from baseline. The TS-PGIC data
were tabulated by visit without missing data imputation, including the
number and percentage of subjects in each rating category by time
point. For the TS-PGIC analyses, a two-sided, Wilcoxon-signed rank
test was performed at each post-baseline time point to test the null
hypothesis that the median score equals zero (no change). Statistical
tests were performed at the 0.05 significance level.
Safety analyses were performed on all subjects who received at least
one dose of study medication. The overall safety and tolerability of
deutetrabenazine was assessed throughout the study by monitoring
AEs, and observed changes from baseline to week 8 clinical visits in
psychometric evaluations, measures of clinical laboratory parameters,
vital signs, neurological examinations, ECG parameters, and the
proportion of patients with on-treatment QTcF values .450 ms,
.480 ms, and .500 ms.
Results
Participant disposition
A total of 23 patients (17 males), mean (SD [standard deviation])
age 16 (2.3) years were enrolled in the study, received a dose of
deutetrabenazine, and had at least one post-baseline YGTSS asses-
sment. Three (13%) patients did not complete the study; one withdrew
because of an AE (i.e., non-serious irritability unrelated to treatment)
on day 15 of the study, one withdrew for administrative reasons at
week 1, and one did not complete the follow-up visit at week 9. There
were no poor metabolizers and three patients were ultrarapid
metabolizers on the basis of blinded CYP2D6 genotyping at screening.
During the 8-week treatment period, the mean (SD) percent com-
pliance rate was 93.8 (9.4).
Participant characteristics
The mean (SD) baseline TTS was 31.6 (7.92) and the mean (SD)
baseline TIS was 34.3 (9.45). The mean (SD) TS-CGI baseline score
was 4.7 (0.88), which characterized the presence of moderate to
marked tics. At baseline 18 out of 23 (78.3%) patients were receiving
concomitant medications. The most frequently prescribed medications
were psychostimulants (35%), antidepressants (26%), and non-steroidal
anti-inflammatory agents (26%). At the end of titration (week 6), the
mean (SD) daily dose of deutetrabenazine was 31.7 mg (7.14 mg).
At the end of the treatment period (week 8), 14 patients were dosed
at 36 mg, three at 30 mg, one at 24 mg, and three patients were taking
18 mg per day. The mean (SD) daily dose at week 8 was 32.0 mg
(6.7 mg). The three patients genotyped as ultrarapid metabolizers,
received a daily dose of 36 mg, the maximum allowed dose, possibly
suggesting that these rapid metabolizers require a higher dose.
Efficacy
The mean (SD) change in the TTS from baseline to week 8 (primary
outcome measure), as assessed by a blinded rater, was 11.6 (8.18)
representing a mean (SD) percent reduction of 37.6% (27.15) with
95% CI –49.96 to –25.24 (p,0.0001, Figure 2). This reduction in
TTS is almost twice the reported clinically meaningful change of 25%
by Joen, et al.21 In our study 61.9% of treated patients achieved this
clinically meaningful change. Although the studies or populations are
not comparable, this is higher than the figure of 51.3% reported in
patients treated with Comprehensive Behavioral Intervention for
Tics.21
Mean (SD) baseline YGTSS subscores were GSS566.0 (16.0),
Motor Tic Severity Score 5 17.4 (3.9), Vocal Tic Severity Score5
14.2 (5.7), and TIS534.3 (9.4), and were reduced by 36.7%, 34.98%,
44.31%, and 35.3% respectively (all p,0.0001, Table 1). Upon
withdrawal of the drug, the mean (SD) TTS increased by 5.6 points
from week 8 to week 9, supporting the efficacy observed during the
8-week treatment period.
Figure 1. Study Design. Timeline of in-person and telephone visits and a list of assessments at each visit. Abbreviations: YGTSS, Yale Global Tic Severity Scale;
TS-CGI, Tourette’s Syndrome Clinical Global Impression; PGIC, Patient Global Impression of Change (administered at weeks 2, 4, 8, and 9 only), CY-BOCS,
Children’s Yale–Brown Obsessive–Compulsive Scale; BDI-II, Beck Depression Inventory; C-SSRS, Columbia Suicide Severity Rating Scale.
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At week 8, treatment with deutetrabenazine resulted in a statistically
significant (p,0.0001) decrease in the mean (SD) TS-CGI from the
observed score at baseline (Table 1). Clinical improvement was
observed in the majority of patients, with 85.7% of patients having at
least a 1-point score improvement in the TS-CGI from baseline to
week 8. At baseline the mean (SD) TS-CGI score was 4.7 (0.88), which
represented moderate to marked TS, whereas at week 8, the mean
(SD) score observed was 3.6 (1.16), which represented mild to
moderate TS (Figure 3). At week 8, all patients noted improvement
on the TS-PGIC, with the majority of patients (76.2%) reporting that
they were ‘‘much improved’’ or ‘‘very much improved’’ (p,0.0001,
Figure 4). The mean (SD) deutetrabenazine exposure was 54 (9.3) days
(range 15–65 days).
Safety and tolerability
All AEs reported were mild to moderate in severity, and there were
no severe AEs, serious AEs, or deaths reported in the study. During
the treatment period, which included the titration and maintenance
periods, 15 out of 23 (65.2%) patients experienced AEs; the most
frequent AEs were fatigue (four; 17%), headache (four; 17%),
irritability (three; 13%), somnolence (two; 8%), hyperhidrosis (two;
8%), diarrhea (two; 8%), and nasopharyngitis (two; 8%). One patient
reported symptoms consistent with suicidal ideation at week 8 based on
the C-SSRS; this event was considered mild and not treatment related
by the investigator, who felt that it was more related to the patient’s
prior history of fluctuating mood; the suicidal thoughts resolved 9 days
later without treatment or dose change. One patient withdrew from
the study because of irritability that was considered non-serious and
not treatment related by the investigator during the titration period.
This patient’s medical history included receiving risperidone 1 mg for
irritability because of ADHD. The risperidone treatment was dis-
continued prior to study entry and once the patient discontinued from
the study, risperidone treatment was reinstated and the irritability resolved.
Mean (min–max) QTcF at the screening visit was 398 (354–434) and
at week 8 was 402 (379–426).
Discussion
Our phase 1b clinical trial of deutetrabenazine provides evidence
that this VMAT2 inhibitor, at doses up to 36 mg/day, may be a safe
and effective tic-reducing drug. This conclusion is supported by 37.6%
(p,0.0001) reduction in the TTS, as assessed by a blinded rater
following 8 weeks of deutetrabenazine treatment, and by a limited
number of adverse events. In addition, there were significant impro-
vements in the other prespecified efficacy endpoints including TIS,
TS-CGI, and TS-PGIC. There was also improvement in the BDI-II
and CY-BOCS measures of depression and obsessive–compulsive
symptoms. It is not clear why the YGTSS scores 1 week following
withdrawal did not return to baseline levels (Figure 2). Although it is
possible that the drug may not have completely washed out by week 9,
larger and longer studies are needed in the future to address this issue.
Figure 2. Changes in Total Tic, Motor, and Phonic Tic Scores over Time. Primary efficacy scores were change in mean TTS scores at week 8 following
6 weeks of titration and 2 weeks maintenance dosing with deutetrabenazine. The graph illustrates a reduction in TTS, motor and phonic tic mean scores to week 8
(all p,0.001). When deutetrabenazine was withdrawn, the total and individual scores increased until the last assessment at week 9. Error bars represent the standard
deviations. Abbreviations: YGTSS, Yale Global Tic Severity Scale; TTS, YGTSS Total Tic Score; Motor Tic Score, Motor; Vocal Tic Score, Phonic.
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Because of the small sample size and short duration of treatment we
did not feel it was appropriate or possible to perform correlative
analyses to determine if the results were influenced by the presence of
various comorbidities, other medications, or by the subjects’ CYP2D6
genotype.
Currently, only haloperidol, pimozide, and aripiprazole are app-
roved by the FDA for the treatment of TS. These neuroleptics,
however, have limited usefulness as they are frequently associated with
a variety of undesirable AEs, including drowsiness, weight gain, and
metabolic syndrome and the potential to cause tardive dyskinesia,22–24
although the occurrence of TD is rare in adolescents with TS.25
VMAT2 inhibitors, such as tetrabenazine, which act primarily by
depleting presynaptic dopamine rather than by blocking postsynaptic
dopamine receptors, have not been documented to cause TD.26
Table 1. Mean Change from Baseline to Week 8
Assessment Mean (SD) [95% CI for mean]1 Change from Baseline
At Week 8
TTS
Baseline 31.6 (7.9) [28.2, 35.0] -11.6 (8.2) [-15.3, -7.8]
p , 0.00012Week 8 20.8 (11.4) [15.6, 25.9]
TIS
Baseline 34.3 (9.4) [30.3, 38.4] -11.9 (9.3) [-16.1, -7.7]
p , 0.0001Week 8 22.9 (11.5) [17.6, 28.1]
GSS
Baseline 66.0 (16.0) [59.0, 72.9] 23.5 (15.7) [-30.6, -16.3]
p , 0.0001Week 8 43.6 (22.0) [33.6, 53.7]
MTSS
Baseline 17.4 (3.9) [15.7, 19.1] -6.1 (4.3) [-8.1, -4.1]
p , 0.0001Week 8 11.7 (5.4) [9.2, 14.1]
VTSS
Baseline 14.2 (5.7) [11.8, 16.7] -5.5 (4.4) [-7.5, -3.5]
p , 0.0001Week 8 9.1 (6.96) [5.9, 12.3]
TS-CGI
Baseline 4.7 (0.88) [4.3, 5.1] -1.2 (0.81) [-1.6, -0.8]




1 point rating minimally improved n = 5 (23.8%)
2 point rating much improved n = 12 (57.1%)
3 point rating very much improved n = 4 (57.1%)
p , 0.0001
BDI-II
Baseline 14.2 (13.9) (0-52)3 21; -5.7 (8.0) (-25, -5)
-2.7 (5.5) (-23, 0)
p 5 0.0352
Week 8 8.2 (11.6) (0-33)
CY-BOCS4
Baseline 7.0 (9.2) (0-27)
Week 8 4.5 (7.5) (0-25)
Abbreviations: BDI, Beck Depression Inventory; CGI, Clinical Global Impression; CI, Confidence Interval; CY-BOCS, Children’s
Yale–Brown Obsessive Compulsive Scale; GSS, Global Severity Score; max, Maximum; min, Minimum; MTSS, Motor Tic Severity Score;
PGIC, Patient Global Impression of Change; SD, Standard Deviation; TIS, Tic-Related Impairment Score; TS, Tourette Syndrome; TTS,
Total Tic Severity Score; VTSS, Vocal Tic Severity Score.
1Confidence interval based on the t-distribution.
2p-values are from two-sided one sample t-tests performed on the change from baseline to week 8 for all endpoints except TS-PGIC for which
the Wilcoxon--signed rank test was performed
3BDI-II minimum and maximal values provided instead of 95% CI limits
45 patients had baseline values .16 for CY-BOCS total score
n 5 23 for baseline measures and n 5 21 for Week 8 assessments
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Indeed, tetrabenazine and novel VMAT2 inhibitors, such as deute-
trabenazine and NBI-98854,27,28 are currently under clinical investi-
gation for the treatment of TD.
The results from our study are similar to the treatment effects
demonstrated with tetrabenazine,7–9, fluphenazine,29 topiramate,30 aripi-
prazole,31 and other drugs used to treat TS.1,4,32 Deutetrabenazine was
well tolerated (the most common AEs were fatigue, headache, and
irritability) and there were no serious AEs, such as depression. Other AEs
commonly associated with tetrabenazine, such as parkinsonism and
akathisia, were not observed with deutetrabenazine in our study sample.
Based on the known pharmacokinetics of deutetrabenazine, it was pre-
dicted that the drug would be associated with a relatively low risk of
drowsiness (one of the most common AEs associated with tetrabenazine),
which tends to correlate with an initial steep rise in blood and brain
levels. Indeed in this study, only two (8.7%) of the patients receiving
deutetrabenazine experienced somnolence, compared with 36.4% of
patients in an open-label retrospective study of patients taking tetra-
benazine for TS.8 Another advantage of deutetrabenazine over tetra-
benazine is that it can be administered only twice per day instead of three
or more times per day. This should improve medication adherence,
especially for children and adolescents. Although this study was relatively
short in duration, deutetrabenazine, similar to tetrabenazine, is expected
to have a low or no risk of tardive dyskinesia, which is one of the most
feared AEs of neuroleptics currently approved by the FDA or used off-
label for the treatment of TS.22–24
There are several limitations to this study that must be acknowl-
edged, including a small sample size, limited dosing, open-label design,
lack of a placebo control, and short duration of treatment relative to
natural fluctuations of tics. Because this was a pilot study no inter-rater
reliability was conducted, but we ensured that all raters at each center
had previous experience at assessing YGTSS scores. Assessments by
independent (‘‘blinded’’) raters may have partially mitigated the lack of
a placebo-treated group. Despite these limitations, we believe that the
results of this study support further development of deutetrabenazine
for the treatment of TS. These preliminary data, while encouraging,
should be viewed cautiously and must be validated by a longer, larger
double-blind, placebo-controlled trial currently being planned in the
United States and Europe.
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